肥厚型心肌病的诊疗进展
解培顺,周长伟
摘要(Abstract)：
肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是以左心室(或)右心室肥厚为特征,常为不对称肥厚并累及室间隔,左心室血液充盈受阻、舒张期顺应性下降为基本病态的一种常染色体显性遗传病,本病常有明显家族史(约占1/3),目前被认为是常染色体显性遗传疾病。根据安静及负荷状态下左心室腔与主动脉瓣下压力阶差,HCM可分为梗阻性肥厚型心肌病、非梗阻性肥厚型心肌病和隐匿梗阻性肥厚型心肌病。近年来,有关HCM的诊疗已取得了较大的进展。
关键词(KeyWords)： 肥厚型心肌病;分子水平研究;新进展
基金项目(Foundation):
作者(Author): 解培顺,周长伟
参考文献(References)：
- [1]Konno T,ChangS,Seidman JG,et al.Genetics of hypertrophic cardiomyopathy[J].Curr Opin Cardio1,2010,25(3):205-209.
- [2]宋艳瑞,刘忠,顾淑莲,等.肥厚型心肌病的致病分子机制研究进展遗传[J].遗传,2011,33(6):549-557.
- [3]Hagège AA,Desnos M.New trends in treatment of hypertrophic cardiomyopathy[J].Arch Cardiovasc Dis,2009,102(5):441-447.
- [4]Maron BJ,Estes NA 3rd,Maron MS,et al.Primary preventinon of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy[J].Circulation,2003,107(23):2872-2875.
- [5]乔树宾,袁建松.肥厚型心肌病的治疗[J].国际心血管病杂志,2011,38(1):9-13.
- [6]Mazur W,Nagueh SF,Lakkis NM,et al.Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy[J].Circulation,2001,103(11):1492-1496.
- [7]Fosslien E.Mitochondrial medicine--cardiomyopathy caused by defective oxidative phosphorylation[J].Ann Clin Lab Sci,2003,33(4):371-395.